Network meta-analysis of triple therapy for the prevention and treatment of acute nausea and vomiting caused by emetogenic chemotherapy drugs with moderate and high risk
OBJECTIVE To evaluate the efficacy of the triple therapy of 5-HT3 receptor antagonists,neurokinin-1 receptor antagonists and dexamethasone(referred to as"triple therapy")in the prevention and treatment of acute nausea and vomiting caused by moderately and highly emetogenic chemotherapy drugs.METHODS Retrieved from PubMed,Embase,the Cochrane Library,CNKI and Wanfang data,randomized controlled trials(RCTs)about triple therapy or 5-HT3 receptor antagonist combined with dexamethasone(referred to as"dual therapy")were collected during the inception to May 2023.After literature screening,data extraction and literature evaluation,network meta-analysis was performed by using Stata 16.0 software.RESULTS A total of 59 RCTs were included,involving 23 418 patients and 15 interventions.Results of network meta-analysis showed that fosaprepitant + palonosetron + dexamethasone(FPD)was most effective in terms of acute nausea and vomiting control rate,followed by fosaprepitant + granisetron + dexamethasone(FGD)and aprepitant + ramosetron + dexamethasone(AMD).In terms of acute nausea control rate,FPD was the most effective,followed by aprepitant + palonosetron + dexamethasone(APD)and FGD.In terms of acute vomiting control rate,FPD was the most effective,followed by FGD and APD.CONCLUSIONS Fosaprepitant + palonosetron + dexamethasone is better than other triple therapy or dual therapy in preventing acute nausea and vomiting caused by moderately and highly emetogenic chemotherapy drugs.
5-HT3 receptor antagonistneurokinin-1 receptor antagonistdexamethasonenausea and vomitingnetwork meta-analysis
万方数据
维普
